Stock Groups

GSK says tests show antibody drug works against Omicron -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: GlaxoSmithKline’s (GSK), logo can be seen at the top of GSK Asia House, Singapore, 21 March 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera/File Photo

By Ludwig Burger

(Reuters) – GlaxoSmithKline (NYSE 🙂 announced Thursday that a laboratory analysis of its antibody-based COVID-19 treatment it has been developing with U.S. collaborator Vir had shown that the drug was effective against Omicron variant.

British drugmaker, Sotrovimab stated in a statement that it has been proven to be effective against Omicron-related viruses through laboratory tests and an experiment on hamsters.

It said that the tests continue to verify the results against Omicron mutations. An update is expected before the end of the year.

On Thursday, Britain’s Drug Regulatory Authority approved sotrovimab (also known as Xevudy) for those with mild or moderate COVID-19 and at risk of severe diseases.

The Medicines and Healthcare products Regulatory Agency, (MHRA), recommended that Xevudy be used as soon as possible and within five working days after onset of symptoms.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of the potential risks and financial costs involved in trading the financial market. It is one the most dangerous investment types.

[ad_2]